Given the inherently elevated baseline cardiovascular risk in patients with T2DM, combined with the challenge of residual dyslipidemia despite maximal statin therapy, there is a compelling need to rigorously evaluate the clinical benefits of PCSK9 inhibitors in this specific high-risk subgroup. This evidence concerns the gene PCSK9 and metabolic syndrome.